Abstracts tagged "C-reactive protein (CRP)"

Abstract Number: 534 • 2014 ACR/ARHP Annual Meeting
Serum Biomarkers of Inflammation and Fibrosis in Advancing Diagnosis, Prognosis and Treatment of Anti-Ro Associated Congenital Heart Block
Amit Saxena¹, Peter M. Izmirly², Sung Won Han³, Andrew Markham⁴, Robert M. Clancy⁵ and Jill P. Buyon⁵, ¹Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Department of Population Health, New York University School of Medicine, New York, NY, ⁴Medicine, New York University School of Medicine, New York, NY, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose Women with Sjogren’s Syndrome (SS) and anti-Ro antibodies face the risk of a pregnancy complicated by fetal congenital heart block (CHB). Identification of maternal…
Abstract Number: 376 • 2014 ACR/ARHP Annual Meeting
Using the Multi-Biomarker Disease Activity Score As a Complementary Inclusion Criterion for Clinical Trials in Rheumatoid Arthritis May Enhance Recruitment
Ronald F. van Vollenhoven¹, Rebecca J. Bolce², Karen Hambardzumyan³, Saedis Saevarsdottir⁴, Kristina Forslind⁴, Ingemar Petersson⁵, Eric H. Sasso², CC Hwang⁶, Oscar Segurado² and Pierre Geborek⁷, ¹Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³ClinTRID, the Karolinska Institute, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Department of Orthopedics, Clinical Sciences Lund, Lund, Sweden, ⁶Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, ⁷Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose Clinical trials in rheumatoid arthritis (RA) often require elevated C-reactive protein (CRP) as an inclusion criterion, which may limit recruitment by excluding some patients…
Abstract Number: 1421 • 2013 ACR/ARHP Annual Meeting
Treatment Responses and Their Predictors Of Abatacept In Biologic naïve Patients With Rheumatoid Arthritis; Data Form Abroad Study
Yutaka Kawahito¹, Takao Fujii², Akira Yokota³, Hideo Hashimoto⁴, Kiyoshi Matsui⁵, Kenji Miki⁶, Masayasu Kitano⁵, Naoki Shinmyo⁷, Aihiro Yamamoto¹, Koichiro Ohmura⁸, Takanori Kuroiwa⁹, Toshihiko Hidaka¹⁰, Ichiro Yoshii¹¹, Hideko Nakahara¹², Takashi Fujimoto¹³, Kosaku Murakami¹⁴, Satoshi Morita¹⁵, Masahiro Sekiguchi⁵, Norihiro Nishimoto^16,17, Tsuneyo Mimori⁸ and Hajime Sano⁵, ¹Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ²Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Yokota Clinic for Rheumatology, Osaka, Japan, ⁴Dept of Orthopedic Surgery, Rinku Hashimoto Rheumatology Orthopaedics, Osaka, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan, ⁶Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ⁷Kashiba Asahigaoka Hospital, Kashiba, Japan, ⁸Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁹Department of Rheumatology, Yukioka Hospital, Osaka, Japan, ¹⁰Zenjinkai Shimin-No-Mori Hospital, Miyazaki, Japan, ¹¹Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, ¹²Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ¹³Nara Medical University, Kashihara, Japan, ¹⁴Rheumatology and Clinical Immunology, Osaka Red Cross Hospital, Osaka, Japan, ¹⁵Graduate School of Medicine & Medical Center, Department of Biostatistics and Epidemiology, Yokohama City University, Kanagawa, Japan, ¹⁶Tokyo Medical University, Tokyo, Japan, ¹⁷Osaka Rheumatology Clinic, Osaka, Japan
Background/Purpose: The identification of predictors of good response to biologic therapy is needed in the perspective of personalized medicine.　To determine the predicting factors of efficacy…
Abstract Number: 532 • 2013 ACR/ARHP Annual Meeting
Role Of Baseline C-Reactive Protein In Response To Infliximab Plus Naproxen Vs Naproxen Alone In Patients With Axial Spondyloarthritis
J Sieper¹, M Rudwaleit¹, J Lenaerts², J Wollenhaupt³, L Myasoutova⁴, S Park⁵, Y Song⁶, R Yao⁷, M Govoni⁸, D Chitkara⁹ and N Vastesaeger¹⁰, ¹University Clinic Benjamin Franklin, Berlin, Germany, ²Practice Rheumatology, Hasselt, Belgium, ³Schön-Klinik, Hamburg, Germany, ⁴Kazan State Medical University, Kazan, Russia, ⁵Catholic University of Korea, Seoul, South Korea, ⁶Seoul National University, Seoul, South Korea, ⁷Merck & Co., Inc., Whitehouse Station, NJ, ⁸MSD Italy, Rome, Italy, ⁹Merck Sharp & Dohme, Kenilworth, NJ, ¹⁰Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Baseline inflammation has been shown to influence response to tumor necrosis factor alpha antagonist treatment in patients with axial spondyloarthritis (SpA). This study evaluated…
Abstract Number: 245 • 2013 ACR/ARHP Annual Meeting
C-Reactive Protein But Not Erythrocyte Sedimentation Rate Is Associated With Decrease In Muscle Strength In Patients With Knee Osteoarthritis: A 2 Year Follow Up Study
Diana C Sanchez-Ramirez¹, Marike van der Leeden², Martin van der Esch³, Leo D. Roorda², Sabine Verschueren⁴, Jaap van Dieen⁵, Joost Dekker⁶ and Willem F. Lems⁷, ¹Human movement sciences, VU university Amsterdam, Amsterdam, Netherlands, ²Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ³Amsterdam Rehabilitation Research Center, Reade, Amsterdam, Netherlands, ⁴Department of Rehabilitation Sciences, KU University of Leuven, Leuven, Belgium, ⁵Faculty of Human Movement Sciences, VU University, Amsterdam, Netherlands, ⁶Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands, ⁷Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: In patients with knee osteoarthritis activity limitations and disease progression have been associated with muscle weakness (OA). Muscle weakness might be determined by factors…
Abstract Number: 162 • 2013 ACR/ARHP Annual Meeting
Genotypic and Haplotypic Effects Of 7 Single-Nucleotide Polymorphisms In the CRP Gene On Levels Of C-Reactive Protein and DAS28 In a Cohort Of 180 Untreated Newly Diagnosed Rheumatoid Arthritis Patients (OPERA Study)
Christian G. Ammitzbøll¹, Rudi Steffensen², Peter Junker³, Mikkel Østergaard⁴, Julia Johansen⁵, Jan Pødenphant⁶, Merete Lund Hetland^7,8, Hanne M. Lindegaard⁹, Torkell Ellingsen¹⁰ and Kristian Stengaard-Pedersen¹, ¹Arhus University Hospital, Aarhus, Denmark, ²Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark, ³University of Southern Denmark, Odense, Denmark, ⁴Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ⁵Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, ⁶Copenhagen University at Gentofte, Hellerup, Denmark, ⁷Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ⁹Department of Rheumatology, Odense University Hospital, Odense, Denmark, ¹⁰Department of Internal Medicine, Diagnostic Centre Region Hospital Silkeborg Denmark, 8600 Silkeborg, Denmark
Background/Purpose: Single nucleotide polymorphisms (SNPs) in the CRP gene are implicated in the regulation of the basal C-reactive protein (CRP) expression and its response to…
Abstract Number: 2683 • 2013 ACR/ARHP Annual Meeting
Application Of a Multi-Biomarker Disease Activity (Vectra^® DA) Score For Assessing Rheumatoid Arthritis Patients With Fibromyalgia Or Low C-Reactive Protein
Yvonne C. Lee¹, James Hackett², Claire Alexander³, Michelle A. Frits¹, Christine K. Iannaccone¹, Nancy A. Shadick⁴, Michael E. Weinblatt⁵, Oscar Segurado⁶ and Eric H. Sasso⁶, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Hackett & Associates, Inc., San Diego, CA, ³Clinical Operations, Crescendo Bioscience Inc., South San Francisco, CA, ⁴Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, ⁵Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA, ⁶Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: Clinical assessment of rheumatoid arthritis (RA) may be challenging if patients have fibromyalgia (FM) or if C-reactive protein (CRP) is low (£1 mg/dL). A…
Abstract Number: 2333 • 2013 ACR/ARHP Annual Meeting
Association Of Mean Changes In Laboratory Safety Parameters With C-Reactive Protein At Baseline and Week 12 In Rheumatoid Arthritis Patients Treated With Tofacitinib
V. Strand¹, J. D. Isaacs², S. Menon³, J. Beal⁴, C. I. Nduaka⁵, S. Krishnaswami³, R. Riese⁵ and M.G. Boy⁵, ¹Stanford University, Palo Alto, CA, ²Newcastle University, Newcastle-upon-Tyne, United Kingdom, ³Clinical Pharmacology, Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Changes in laboratory parameters observed during tofacitinib treatment…
Abstract Number: 1788 • 2013 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Test (Vectra^® DA) Estimates Risk Of Radiographic Progression For Patients With Rheumatoid Arthritis From The Leiden Early Arthritis Clinic
Wanying Li¹, DJ Haney¹, Guy Cavet¹, Thomas W. Huizinga², Eric H. Sasso¹ and A. H. M. van der Helm-van Mil³, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The multi-biomarker disease activity (MBDA) blood test assesses disease activity in patients with rheumatoid arthritis (RA) using a validated algorithm to provide a score…
Abstract Number: 1790 • 2013 ACR/ARHP Annual Meeting
Serum Amyloid A Levels Model Rheumatoid Arthritis Disease Activity Better Than C-Reactive Protein Levels Especially During Treatment With Anti-Tumor Necrosis Factor α Therapy (Etanercept)
Ilinca D. Metes¹, Douglas W. Chew², Aarat M. Patel¹, G.K. Balasubramani³, Jeffrey R. Curtis⁴, S. Louis Bridges Jr.⁵, Stephen R. Wisniewski⁶, Larry W. Moreland⁷ and Marc C. Levesque⁸, ¹Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁷Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA
Background/Purpose: C reactive protein (CRP) levels have been used extensively to model disease activity in rheumatoid arthritis (RA). However, TNF antagonist therapy (and likely therapy…
Abstract Number: 1473 • 2013 ACR/ARHP Annual Meeting
Anti-Tumor Necrosis Factor α Therapy (Etanercept) Plus Methotrexate Lowers Serum Amyloid A Levels To a Greater Extent Than Triple Oral Disease Modifying Anti-Rheumatic Drug Therapy In Early Rheumatoid Arthritis Subjects
Ilinca D. Metes¹, Douglas W. Chew¹, Aarat M. Patel¹, G.K. Balasubramani², S. Louis Bridges Jr.³, Jeffrey R. Curtis⁴, Stephen R. Wisniewski², Larry W. Moreland⁵ and Marc C. Levesque⁶, ¹Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ³Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Amyloidosis is often due to an underlying inflammatory disorder, such as rheumatoid arthritis (RA), with organ deposition of serum amyloid A (SAA). Oral disease…
Abstract Number: 2661 • 2012 ACR/ARHP Annual Meeting
Disease Activity Score 28-Joint Count: Are Erythrocyte Sedimentation Rate and C-Reactive Protein Versions Comparable?
Roy Fleischmann¹, Désirée van der Heijde², Andrew S. Koenig³, Ronald Pedersen³, Annette Szumski⁴, Lisa Marshall⁵ and Eustratios Bananis⁴, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA, ⁵Pfizer Inc., Collegeville, PA
Background/Purpose: Frequently DAS28-CRP is utilized instead of DAS28-ESR to assess rheumatoid arthritis (RA) disease activity; however, values for remission and low disease activity (LDA) for…
Abstract Number: 2382 • 2012 ACR/ARHP Annual Meeting
Plasma Fibrinogen is an Accurate Marker of Disease Activity in Patients with Polymyalgia Rheumatica
E.M. McCarthy¹, Paul A. MacMullan¹, S. Al-Mudhaffer¹, Anne M. Madigan¹, S. Donnelly¹, C. J. McCarthy¹, Dermot Kenny², Eamonn Molloy³ and G M. McCarthy¹, ¹Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ²Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ³Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Accurate determination of disease activity in polymyalgia rheumatica(PMR) is challenging due to the subjective nature of symptoms and concurrent musculoskeletal complaints in an elderly…
Abstract Number: 2348 • 2012 ACR/ARHP Annual Meeting
Plasma Fibrinogen Better Identifies Persistent Disease Activity in Polymyalgia Rheumatica Than Either ESR or CRP
EM McCarthy¹, Paul A. MacMullan¹, S. Al-Mudhaffer¹, Anne M. Madigan¹, S. Donnelly¹, C. J. McCarthy¹, Dermot Kenny², Eamonn Molloy³ and G M. McCarthy¹, ¹Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ²Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ³Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: In PMR careful tailoring of the glucocorticoid dosage to the patients needs is crucial to avoid the risk of treatment-related adverse effects and the…
Abstract Number: 1344 • 2012 ACR/ARHP Annual Meeting
Diagnostic Value of High Sensitivity C Reactive Protein for Early Axial Spondyloarthritis: Results From the Devenir Des Spondylarthopathies Indifferenciees Recentes Cohort
Victoria Navarro-Compán¹, Désirée van der Heijde², Bernard Combe³, Claudine Cosson⁴ and Floris van Gaalen¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Deptartment of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Biochemistry, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, Paris, France
Background/Purpose: The average delay in spondyloarthritis (SpA) diagnosis after symptom onset is one of the longest among the inflammatory rheumatic diseases. Elevated C-reactive protein (CRP)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].